Castle Hook Partners LP bought a new stake in Astrazeneca Plc (NYSE:AZN – Free Report) during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm bought 8,233 shares of the company’s stock, valued at approximately $1,445,000.
Several other large investors have also recently bought and sold shares of AZN. Boone Capital Management LLC purchased a new position in Astrazeneca during the fourth quarter worth about $39,000. American Trust bought a new stake in shares of Astrazeneca during the fourth quarter valued at approximately $404,000. Guggenheim Capital LLC grew its holdings in Astrazeneca by 2.4% in the fourth quarter. Guggenheim Capital LLC now owns 195,602 shares of the company’s stock worth $34,328,000 after purchasing an additional 4,538 shares during the last quarter. ADAR1 Capital Management LLC acquired a new position in Astrazeneca during the fourth quarter valued at $1,580,000. Finally, Bank OZK acquired a new position in shares of Astrazeneca in the fourth quarter worth about $4,270,000. 20.35% of the stock is currently owned by institutional investors.
Astrazeneca Price Performance
Shares of NYSE AZN opened at $178.09 on Thursday. Astrazeneca Plc has a twelve month low of $137.23 and a twelve month high of $212.71. The company has a quick ratio of 0.71, a current ratio of 0.91 and a debt-to-equity ratio of 0.52. The stock’s 50-day simple moving average is $187.81 and its two-hundred day simple moving average is $186.21. The firm has a market capitalization of $276.20 billion, a P/E ratio of 26.74, a P/E/G ratio of 1.55 and a beta of 0.25.
Analysts Set New Price Targets
A number of equities research analysts have recently weighed in on the stock. Wall Street Zen upgraded shares of Astrazeneca from a “hold” rating to a “buy” rating in a report on Saturday, May 2nd. DZ Bank upgraded shares of Astrazeneca from a “neutral” rating to a “buy” rating in a research report on Wednesday, April 29th. Sanford C. Bernstein reissued a “buy” rating on shares of Astrazeneca in a research report on Monday, May 4th. UBS Group restated a “buy” rating on shares of Astrazeneca in a research note on Friday, April 10th. Finally, Morgan Stanley restated an “overweight” rating on shares of Astrazeneca in a research note on Wednesday, April 8th. Twelve investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $205.33.
Check Out Our Latest Stock Report on Astrazeneca
About Astrazeneca
AstraZeneca plc is a global biopharmaceutical company headquartered in Cambridge, England. Formed through the 1999 merger of Sweden’s Astra AB and the UK’s Zeneca Group, the company researches, develops, manufactures and commercializes prescription medicines across a range of therapeutic areas. AstraZeneca positions itself as R&D-driven, investing in discovery science, clinical development and regulatory processes to bring new therapies to market.
The company’s commercial portfolio and late-stage pipeline emphasize oncology, cardiovascular, renal and metabolic (CVRM) diseases, and respiratory and immunology.
See Also
- Five stocks we like better than Astrazeneca
- Cheap Thrills: Why These 3 Entertainment Stocks Are Soaring
- CoreWeave Insider Sales Look Big, But Should Investors Worry?
- Critical Metals: Sizing Up This Tiny Rare-Earth Stock Making Big Moves
- Meta and Cloud Computing: Real Potential, or a Shot in the Dark?
Want to see what other hedge funds are holding AZN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Astrazeneca Plc (NYSE:AZN – Free Report).
Receive News & Ratings for Astrazeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Astrazeneca and related companies with MarketBeat.com's FREE daily email newsletter.
